Low-dose losartan therapy reduces proteinuria in normotensive patients with immunoglobulin a nephropathy

Hypertension Research

Volumn 31, Issue 9, 2008, Pages 1711-1717

  Shimizu, Ari ^a   Takei, Takashi ^a   Uchida, Keiko ^a   Tsuchiya, Ken ^a   Nitta, Kosaku ^a  

^a TOKYO WOMEN'S MEDICAL UNIVERSITY   (Japan)

Author keywords

Angiotensin II receptor blocker; Immunoglobulin A nephropathy; Normotensive; Proteinuria

Indexed keywords

ANGIOTENSIN 2 RECEPTOR ANTAGONIST; ANTITHROMBOCYTIC AGENT; CREATININE; LOSARTAN; N ACETYL BETA GLUCOSAMINIDASE;

ADOLESCENT; ADULT; ARTICLE; BIOCHEMISTRY; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CREATININE BLOOD LEVEL; DIASTOLIC BLOOD PRESSURE; DISEASE SEVERITY; FEMALE; GLOMERULUS FILTRATION RATE; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMMUNOGLOBULIN A NEPHROPATHY; KIDNEY FUNCTION; LOW DRUG DOSE; MALE; PROSPECTIVE STUDY; PROTEINURIA; RANDOMIZED CONTROLLED TRIAL; SYSTOLIC BLOOD PRESSURE;

EID: 55449114221     PISSN: 09169636     EISSN: 13484214     Source Type: Journal    
DOI: 10.1291/hypres.31.1711     Document Type: Article

References (41)

1. D'Amico G: The commonest glomerulonephritis in the world: IgA nephropathy. Q J Med 1987; 245: 709-727.
2. Koyama A, Igarashi M, Kobayashi M: Natural history and risk factors for immunoglobulin A nephropathy in Japan. Research Group on Progressive Renal Diseases. Am J Kidney Dis 1997; 29: 526-532.
3. Radford MG Jr, Donardio JV Jr, Bergstralh EJ, Grande JP: Predicting renal outcome in IgA nephropathy. J Am Soc Nephrol 1997; 8: 199-207.
4. Maschio G, Alberti D, Janin G, et al: Effect of the angiotensin. converting enzyme inhibitor benazepril on the progression of chronic renal insufficiency. The Angiotensin-Converting-Enzyme Inhibition in Progressive Renal Insufficiency Study Group. N Engl J Med 1996; 334: 939-945.
5. Matsusaka T, Hymes J, Ichikawa I: Angiotensin in progressive renal diseases: theory and practice. J Am Soc Nephrol 1996; 7: 2025-2043.
6. 1 receptor blocker, on the glomerular fibrosis of IgA nephropathy in ddY mice. Nephron 2000; 86: 374-375.
7. Park HC, Xu ZG, Choi S: Effect of losartan and amlodipine on proteinuria and transforming growth factor-β1 in patients with IgA nephropathy. Nephrol Dial Transplant 2003; 18: 1115-1121.
8. Song JH, Lee SW, Suh JH: The effects of dual blockade of the renin-angiotensin system on urinary protein and transforming growth factor-beta excretion in 2 groups of patients with IgA and diabetic nephropathy. Clin Nephrol 2003; 60: 318-326.
9. Li PK, Leung CB, Chow KM, et al, HKVIN Study Group: Hong Kong Study Using Valsartan in IgA Nephropathy (HKVIN): a double-blind, randomized, placebo-controlled study. Am J Kidney Dis 2006; 47: 751-760.
10. Russo D, Pisani A, Balletta MM, et al: Additive antiproteinuric effect of converting enzyme inhibitor and losartan in normotensive patients with IgA nephropathy. Am J Kidney Dis 1999; 33: 851-856.
11. Horita Y, Tadokoro M, Taura K, et al: Low-dose combination therapy with temocapril and losartan reduces proteinuria in normotensive patients with immunoglobulin A nephropathy. Hypertens Res 2004; 27: 963-970.
12. Imai E, Horio M, Nitta K, et al: Modification of the Modification of Diet in Renal Disease (MDRD) Study equation for Japan. Am J Kidney Dis 2007; 50: 927-937.
13. Taneda S, Honda K, Nitta K, et al: Clinicopathological study of IgA nephropathy in adults: the influence of onset age on clinical and renal histological findings and on the effect of steroid therapy. Clin Exp Nephrol 1999; 3: 96-103.
14. Maschio G, Alberti D, Locatelli F, et al: Angiotensin-converting enzyme inhibitors and kidney protection: the AIPRI trial. The ACE Inhibition in Progressive Renal Insufficiency (AIPRI) Study Group. J Cardiovasc Pharmacol 1999; 33 (Suppl 1): S16-S20.
15. Ruggenenti P, Perna A, Gherardi G, Gaspari F, Benini R, Remuzzi G: Renal function and requirement for dialysis in chronic nephropathy patients on long-term ramipril: REIN follow-up trial. Gruppo Italiano di Studi Epidemiologici in Nefrologia (GISEN). Ramipril Efficacy in Nephropathy. Lancet 1998; 352: 1252-1256.
16. Burnier M, Brunner RH: Angiotensin II receptor antagonists. Lancet 2000; 355: 637-645.
17. Murayama S, Hirano T, Sakaue T, Okada K, Ikejiri R, Adachi M: Low-dose candesartan cilexetil prevents early kidney damage in type 2 diabetic patients with mildly elevated blood pressure. Hypertens Res 2003; 26: 453-458.
18. Gansevoort RT, de Zeeuw D, de Jong PE: Is the antiproteinuric effect of ACE inhibition mediated by interference in the renin-angiotensin system? Kidney Int 1994; 45: 861-867.
19. Nielsen S, Dollerup J, Nielsen B, et al: Losartan reduces albuminuria in patients with essential hypertension. An enalapril controlled 3 month study. Nephrol Dial Transplant 1997; 12 (Suppl 2): 19-23.
20. Praga M, Fernández Andrade C, Luño J, et al: Antiproteinuric efficacy of losatan in comparison with amlodipine in non-diabetic proteinuria renal diseases: a double-blind, randomized clinical trial. Nephrol Dial Transplant 2003; 18: 1806-1813.
21. Chan JCN, Critchley JA, Tomlinson B, et al: Antihypertensive and anti-albuminuric effects of losartan potassium and felodipine in Chinese elderly hypertensive patients with or without non-insulin dependent diabetes mellitus. Am J Nephrol 1997; 17: 72-80.
22. Fernández Andrade C, Russo D, Iversen B, et al: Comparison of losartan and amlodipine in renally impaired hypertensive patients. Kidney Int 1998; 54 (Suppl 68): S120-S124.
23. Holdaas H, Hartmann A, Berg KJ, et al: Renal effects of losartan and amlodipine in hypertensive patients with nondiabetic nephropathy. Nephrol Dial Transplant 1998; 13: 3096-3102.
24. Anderson S, Meyer TW, Rennke HG, Brenner BM: Control of glomerular hypertension limits glomerular injury in rats with reduced renal mass. J Clin Invest 1985; 76: 612-619.
25. Remuzzi A, Perico N, Sangalli F, et al: ACE inhibition and ANG II receptor blockade improve glomerular size-selectivity in IgA nephropathy. Am J Physiol 1999; 276: F457-F466.
26. Woo KT, Lau YK, Wong KS, Chiang GSC: ACEI/ATRA therapy decreases proteinuria by improving glomerular permselectivity in IgA nephritis. Kidney Int 2000; 58: 2485-2491.
27. Fujita M, Okuda H, Tsukamoto O, et al: Blockade of angiotensin II receptors reduces the expression of receptors for advanced glycation end products in human endothelial cells. Arterioscler Thromb Vasc Biol 2006; 26: e138-e142.
28. Egido J: Vasoactive hormones and renal sclerosis. Kidney Int 1996; 49: 578-597.
29. Remuzzi G, Ruggenenti P, Benigni A: Understanding the nature of renal disease progression. Kidney Int 1997; 51: 2-15.
30. Eddy AA: Molecular insights into renal interstitial fibrosis. J Am Soc Nephrol 1996; 7: 2495-2508.
31. Suzuki K, Han GD, Miyauchi N, et al: Angiotensin II type 1 and type 2 receptors play opposite roles in regulating the barrier function of kidney glomerular capillary wall. Am J Pathol 2007; 170: 1841-1853.
32. Hale GM, Howarth GS, Aarons I, et al: Quantitation of glomerular angiotensin II receptors in IgA nephropathy. Clin Nephrol 1989; 32: 5-9.
33. Kagami S, Border WA, Miller DE, Nobel NA: Angiotensin II stimulates extracellular matrix protein synthesis through induction of transforming growth factor-β expression in rat glomerular mesangial cells. J Clin Invest 1994; 93: 2431-2437.
34. Lewis JB, Berl T, Bain RP, Rohde RD, Lewis EJ: Effect of intensive blood pressure control on the course of type 1 diabetic nephropathy. Collaborative Study Group. Am J Kidney Dis 1999; 34: 809-817.
35. Remuzzi G: Renoprotective effect of ACE inhibitors: dissecting the molecular clues and expanding the blood pressure goal. Am J Kidney Dis 1999; 34: 951-954.
36. Csiky B, Kovács T, Wágner L, Vass T, Nagy J: Ambulatory blood pressure monitoring and progression in patients with IgA nephropathy. Nephrol Dial Transplant 1999; 14: 86-90.
37. Timio M, Venanzi S, Lolli S, et al: "Non-dipper" hypertensive patients and progressive renal insufficiency: a 3-year longitudinal study. Clin Nephrol 1995; 43: 382-387.
38. Uzu T, Ishikawa K, Fujii T, Nakamura S, Inenaga T, Kimura G: Sodium restriction shifts circadian rhythm of blood pressure from nondipper to dipper in essential hypertension. Circulation 1997; 96: 1859-1862.
39. Nishimura M, Uzu T, Fujii T, Kimura G: Disturbed circadian rhythm of urinary albumin excretion in non-dipper type of essential hypertension. Am J Nephrol 2002; 22: 455-462.
40. Bazzi C, Petrini C, Rizza V, et al: Urinary N-acetyl-β-glucosaminidase excretion is a marker of tubular cell dysfunction and a predictor of outcome in primary glomerulonephritis. Nephrol Dial Transplant 2002; 17: 1890-1896.
41. Machiguchi T, Yoshida H, Yonemoto S, et al: Does circulating erythropoietin reflect progression of IgA nephropathy? Comparison with urinary N-acetyl-beta-D-glucosaminidase. Nephrol Dial Transplant 1999; 14: 635-640.